We treated 27 patients with regiona...

We treated 27 patients with regionally advanced non-small-cell lung cancer (NSCLC) with sum of two units cycles of neoadjuvant chemotherapy with etoposide, vindesine, and cisplatin. Twenty-three patients were evaluable for response; 13 had a partial answer while ten patients had stable disease or disease progression. succeeding local therapy consisted of surgery followed from radiotherapy in four patients and of radiotherapy alone in 14 patients. Five patients did not receive local therapy. At completion of local therapy, seven patients were considered unrestrained of disease including all four who had undergone surgery Median time to disease progression for the 13 patients who had a partial answer to neoadjuvant chemotherapy was eight month (three to 51+ months) The median survival for all patients registered onward study was eight months (three days to 53+ months) Chemotherapy induced toxicities included moderate myelosuppression, nausea and vomiting in all patients, and occasional ototoxicity, neurotoxicity, and wasting syndrome individual patient died of intracerebral hemorrhage befitting to thrombocytopenia. This trial point out tos that administration of neoadjuvant chemotherapy to patients with locoregionally advanced NSCLC is feasible and may yield an increased replication rate compared to patients with stage IV disease. While no clearly beneficial drift of the use of chemotherapy forward patient survival is apparent in this inquiry further studies utilizing neoadjuvant chemotherapy in patients with NSCLC are warranted and should attempt to identify more active combinations of remedys (Chest 1989; 96:110-13)

The prognosis for patients with locoregionally advanced (stages IIIA and IIIB) NSCLC remains poor. The majority of patients die of either local and/or distant disease; five-year survival rates of les than 10 percent have been reported for patients with mediastinal or supraclavicular lymph node involvement.[1] Thus, despite apparent locoregional confinement of the disease, aggressive therapy with surgery and/or radiotherapy will consequence in cure for the occasional patient no other than Efforts at improving this grim prognosis of NSCLC have most numerous recently focused on the combined use of multiple therapeutic modalities including neoadjuvant chemotherapy or concomitant chemotherapy and radiotherapy.[2,3]

Neoadjuvant chemotherapy has been applied in a number of solid tumor malignancies.[4,5] It is triped that the initial administration of chemotherapy will lower the locoregional tumor freight and allow for subsequent curative local therapy. In addition, the early use of systemic therapy may eradicate micrometastases and obstruct distant failure. For this universal to be successful, effective systemic chemotherapy is essential. In general, answer rates of patients with stage IV NSCLC to chemotherapy have been disappointing.[6,7] forward the other hand, the experience with neoadjuvant chemotherapy in patients with head and neck cancer moves that higher overall response rates including finished responses can be achieved when administering chemotherapy at an earlier stage in the natural history of the disease. Therefore, in 1983 we decided to inquiry the feasibility of administering neoadjuvant chemotherapy with vindesine, etoposide, and cisplatin to patients with locoregionally advanced NSCLC This analysis portray by actions the final report of this phase II trial.

PATIENTS AND METHODS

Between March 1983 and June 1985 30 patients were inscribeed into this study. Follow-up is available within July 1988. Eligible patients had histologically or cytologically confirmed NSCLC with T2 or T3 primaries and clinically apparent mediastinal or ipsilateral supraclavicular lymph node involvement. A performance status of 0-3 (ECOG) and a 24-hour urine creatinine clearance of 50 ml by minute were also required. All patients were previously untreated and signed informed consent

Initial staging manner of proceedings for all patients consisted of a undiminished history and physical examination, out and out blood count, routine serum chemistries, 24-hour urine creatinine clearance, split pulmonary function studies, chest x-ray film, a CT-scan of the chest including the upper abdomen to the even of the adrenal glands, a bone scan, a liver dumps scan, and a whole material substance gallium scan. Bronchoscopy was performed in all patients; mediastinoscopy or supraclavicular lymph node biopsy was performed to confirm clinically suspicious-appearing mediastinal supraventricular lymph nodes as malignant.

The treatment plan called for sum of two units cycles of neoadjuvant chemotherapy followed according to response evaluation usually consisting of a repeat chest x-ray film and a CT-scan. following local therapy consisted of surgery followed by dint of radiotherapy when the disease was considered resectable by dint of the attending surgeon. Patients with unresectable disease received radiotherapy alone. A flexible number of additional round of yearss of chemotherapy were administered following local therapy unles prohibited on disease progression or cumulative toxicity. Chemotherapy consisted of vindesine, 30 mg/[msup2] at intravenous bolus, and etoposide, 300 mg/m[2] intravenous infusion through the whole extent of 30 to 45 minutes, one as well as the other administered on days 1, 8 15 22 29 and 36 Cisplatin was given intravenously at a dose of 120 mg/[msup2] onward days 1 and 22. Standard hydration and antiemetic schedules were applied.